Anemia, a condition characterized by a decrease in the total amount of red blood cells or hemoglobin in the blood, is a common but complex clinical issue. The diagnosis of anemia requires a systematic approach due to the myriad underlying causes and the wide range of potential presentations.
The initial evaluation of a patient suspected to have anemia should include a thorough history and physical examination. This will often provide clues to the etiology of the anemia. The initial laboratory evaluation should include a complete blood count, reticulocyte count, and peripheral smear.
Anemias can be broadly classified into three groups based on the mean corpuscular volume: microcytic, normocytic, and macrocytic. Each group has a distinct set of potential etiologies that must be considered. For example, microcytic anemia is often due to iron deficiency or thalassemia, while macrocytic anemia may be due to vitamin B12 or folate deficiency.
Further diagnostic testing should be guided by the initial evaluation and classification. For example, in a patient with suspected iron deficiency anemia, serum iron studies may be indicated. In a patient with suspected hemolytic anemia, tests such as haptoglobin, lactate dehydrogenase, and direct antiglobulin test may be useful.
The management of anemia should be tailored to the underlying cause. For example, iron deficiency anemia may be managed with oral iron supplementation, while vitamin B12 deficiency may require parenteral therapy. Follow-up is crucial to ensure response to therapy and to monitor for potential complications.
Anemia is a complex clinical issue that requires a systematic diagnostic approach. By understanding the classification and potential etiologies of anemia, and by utilizing appropriate diagnostic testing, healthcare providers can effectively diagnose and manage this common condition.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation